No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Imiglucerase is a hematological drug used to treat Gaucher disease, a rare genetic disorder. It is a recombinant form of the enzyme glucocerebrosidase, which is deficient in patients with Gaucher disease. Imiglucerase is administered intravenously and helps to reduce the accumulation of certain fatty substances in the body. It is the only approved enzyme replacement therapy for Gaucher disease.
Imiglucerase is a highly specialized drug, and the market is relatively small. It is primarily used in the treatment of pediatric patients, and is not approved for use in adults. The drug is also expensive, and is often not covered by insurance.
The market for Imiglucerase is dominated by a few major players, including Sanofi, Pfizer, and Shire. These companies have developed and marketed the drug, and continue to research and develop new treatments for Gaucher disease. Show Less Read more
